Title: BXQ-350: A novel approach to rebalancing the tumor's immune response Abstract Number: 1331 Date: Friday, November 8, 2024 Author: Gilles Tapolsky, PhD, Vice President of Pharmacology, Bexion ...

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

today announced a poster presentation of its lead asset, RLS-0071 (pegtarazimod), will be presented at the 66 th American ...

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia ...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, ...

The Iowa State Lecture Series will host the “2024 Norman Borlaug Lecture: So Our Children Can Eat: Conserving and Protecting ...

Evalyn Regetta won second place in the grades 3-5 division for the school bus safety poster she designed while in fifth grade ...

As the historic Eduardo Matos Moctezuma Lecture Series came to a close in early October, hundreds of students, faculty, and ...

Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024 GlobeNewswire October 23, 2024 SAN FRANCISCO and SINGAPORE ...

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for ...